CG
ANIP icon

Cutler Group’s ANI Pharmaceuticals ANIP Stock Holding History

Cutler Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,000
Closed -$2K – 4145
2018
Q1 		$2K Sell
1,000
-2,500
-71% -$159K ﹤0.01% 3708
2017
Q4 		$1K Sell
3,500
-2,800
-44% -$174K ﹤0.01% 4350
2017
Q3 		$7K Buy
6,300
+3,800
+152% +$181K ﹤0.01% 4068
2017
Q2 		$2K Sell
2,500
-12,600
-83% -$608K ﹤0.01% 5423
2017
Q1 		$45K Buy
15,100
+10,900
+260% +$612K ﹤0.01% 2514
2016
Q4 		$42K Sell
4,200
-8,200
-66% -$501K ﹤0.01% 2713
2016
Q3 		$39K Sell
12,400
-3,600
-23% -$225K ﹤0.01% 2691
2016
Q2 		$1K Sell
16,000
-14,600
-48% -$710K ﹤0.01% 5954
2016
Q1 		$262K Buy
30,600
+28,300
+1,230% +$960K 0.02% 855
2015
Q4 		$32K Buy
+2,300
New +$99K ﹤0.01% 2911

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Cutler Group's ANIP Position: Q2 2018 in Review

Cutler Group sold out of ANI Pharmaceuticals (ANIP) in Q2 2018, closing a stake of 100 shares — an estimated $5K sold.

Cutler Group first reported a position in ANIP in Q4 2015 and held it in 9 quarters. The position peaked at $314K in Q1 2017. 184 funds tracked by Wall St. Rank hold ANIP as of Q2 2018.

  • Cutler Group reported no remaining ANI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Cutler Group sold 100 ANI Pharmaceuticals shares in Q2 2018, an estimated $5K.
  • Cutler Group first reported a position in ANI Pharmaceuticals in Q4 2015 and held it in 9 quarters.
  • Cutler Group's ANI Pharmaceuticals position peaked at $314K in Q1 2017.
  • 184 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2018.

Based on Cutler Group's 13F filing for Q2 2018, filed 10 Aug 2018.